Published in Immunotherapy on January 01, 2010
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res (2011) 1.05
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol (2011) 0.99
Monitoring of in vivo function of superparamagnetic iron oxide labelled murine dendritic cells during anti-tumour vaccination. PLoS One (2011) 0.94
Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood (2010) 0.88
The top five "game changers" in vaccinology: toward rational and directed vaccine development. OMICS (2011) 0.88
Cytotoxic dendritic cells generated from cancer patients. J Immunol (2011) 0.83
Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. J Immunol (2015) 0.79
Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer. Biomed Res Int (2014) 0.78
Investigations of the functional states of dendritic cells under different conditioned microenvironments by Fourier transformed infrared spectroscopy. Biomed Eng Online (2014) 0.76
Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells. Pharmaceuticals (Basel) (2012) 0.76
Monitoring the efficacy of dendritic cell vaccination by early detection of (99m) Tc-HMPAO-labelled CD4(+) T cells. Eur J Immunol (2014) 0.76
Chemokine programming dendritic cell antigen response: part I - select chemokine programming of antigen uptake even after maturation. Immunology (2013) 0.76
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
Chemokine programming dendritic cell antigen response: part II - programming antigen presentation to T lymphocytes by partially maintaining immature dendritic cell phenotype. Immunology (2013) 0.75
The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model. Med Sci Monit (2016) 0.75
Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection. Immune Netw (2014) 0.75
In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep (2016) 0.75
Targeted immunotherapy for pediatric solid tumors. Oncoimmunology (2015) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Stat3 as an oncogene. Cell (1999) 17.39
Taking dendritic cells into medicine. Nature (2007) 11.82
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 7.67
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Natural adjuvants: endogenous activators of dendritic cells. Nat Med (1999) 7.10
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med (2000) 6.20
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med (2001) 5.71
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest (2002) 4.64
Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol (2000) 4.48
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med (1996) 3.82
Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol (2001) 3.81
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 3.67
A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (1995) 3.58
Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol (2004) 3.25
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
Cancer vaccines: between the idea and the reality. Nat Rev Immunol (2003) 3.24
Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med (1993) 2.96
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Dendritic cell subsets in health and disease. Immunol Rev (2007) 2.45
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35
Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity (1998) 2.33
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med (1995) 2.11
Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A (1998) 2.05
Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol (1994) 1.98
Peptide-induced conformational change of the class I heavy chain. Nature (1991) 1.94
Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res (2004) 1.85
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst (2000) 1.85
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 1.82
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med (1999) 1.71
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev (2002) 1.66
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A (1992) 1.62
Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol (2003) 1.53
Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother (2006) 1.53
Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol (2005) 1.48
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol (2008) 1.44
Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med (1985) 1.40
Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol (1994) 1.39
Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol (2003) 1.38
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res (2002) 1.37
Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol (1999) 1.36
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol (2005) 1.34
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother (2007) 1.26
Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res (2006) 1.26
Regulation of the lifespan in dendritic cell subsets. Mol Immunol (2007) 1.23
Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev (2008) 1.22
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med (2004) 1.22
Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol (2003) 1.22
The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol (2001) 1.21
Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother (1998) 1.19
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother (2008) 1.18
Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol (2001) 1.18
The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol (2007) 1.18
Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood (2002) 1.16
Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother (2002) 1.13
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother (2003) 1.11
Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur J Immunol (1999) 1.11
Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother (2009) 1.10
Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res (2005) 1.09
Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res (2002) 1.08
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother (2005) 1.06
Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood (2001) 1.06
Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother (2008) 1.06
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol (2003) 1.06
Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother (2003) 1.05
Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res (2000) 1.03
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother (2006) 1.03
Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol (1999) 1.01
Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int Immunol (2006) 0.99
Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood (2003) 0.99
Dendritic cells: a critical player in cancer therapy? J Immunother (2008) 0.99
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum (2012) 3.38
CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol (2007) 2.08
Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother (2006) 1.53
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol (2008) 1.44
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2013) 1.42
Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood (2002) 1.34
Diagnosis of active tuberculosis in China using an in-house gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol (2009) 1.19
Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood (2002) 1.16
Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother (2009) 1.10
Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood (2011) 1.09
Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother (2003) 1.05
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol (2012) 1.00
Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood (2003) 0.99
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol (2011) 0.99
Engagement of Toll-like receptor 2 on CD4(+) T cells facilitates local immune responses in patients with tuberculous pleurisy. J Infect Dis (2009) 0.93
Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis (2006) 0.91
MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol (2004) 0.91
Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. J Immunol (2010) 0.89
Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis (2008) 0.89
Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood (2010) 0.88
Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. Int J Cancer (2006) 0.88
Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism. J Immunol (2011) 0.87
Late effects in adult survivors of pediatric cancer: a guide for the primary care physician. Am J Med (2012) 0.86
Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. J Immunol (2007) 0.85
Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother (2005) 0.84
The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res (2007) 0.83
Cytotoxic dendritic cells generated from cancer patients. J Immunol (2011) 0.83
Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol (2013) 0.82
Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer (2004) 0.82
Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood (2004) 0.82
Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. J Biomed Biotechnol (2004) 0.81
Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J Leukoc Biol (2008) 0.81
Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literature. J Pediatr Hematol Oncol (2014) 0.81
Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood (2013) 0.80
Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology (2009) 0.80
Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res (2004) 0.80
A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol Cancer Ther (2008) 0.80
Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol Blood Marrow Transplant (2006) 0.79
Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Int J Hyperthermia (2008) 0.79
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J (2007) 0.78
The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int J Hyperthermia (2013) 0.78
Moderate iron overload enhances lipid peroxidation in livers of rats, but does not affect NF-kappaB activation induced by the peroxisome proliferator, Wy-14,643. J Nutr (2002) 0.78
Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Int J Mol Med (2004) 0.77
Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy. Pediatr Blood Cancer (2014) 0.77
Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunol Immunother (2005) 0.77
Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. Oncoimmunology (2012) 0.77
DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens. Cell Immunol (2010) 0.76
Diagnostic and treatment challenges for the pediatric hematologist oncologist in endemic areas for coccidioidomycosis. J Pediatr Hematol Oncol (2012) 0.76
Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperthermia (2013) 0.76